UK court overturns Genentech patent, cites Brexit in CJEU referral

The patents division of the English High Court has found that a patent owned by Genentech is invalid and denied the biotechnology company’s application for a supplementary protection certificate (SPC).

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Big Pharma

UK govt’s £20m fund for life sciences opens for applications

8 April 2021 The UK government’s £20 million fund aimed at growing life sciences manufacturing is now open for applications, it confirmed today, April 7.

Big Pharma

Genentech to face revived Hemlibra claims

28 August 2020 Genentech and Chugai Pharmaceutical will have to face claims that its haemophilia drug Hemlibra (emicizumab-kxwh) infringed a patent owned by Takeda subsidiary Baxalta.

Big Pharma

Eli Lilly claims another victory in Taltz patent battle

18 February 2020 The English High Court has invalidated key claims of a patent owned by Roche subsidiary Genentech, following a lawsuit filed by US rival Eli Lilly.

More features

Killing the golden goose of US drug innovation (Part II): Drug pricing myths

Former pharma GC brings in-house perspective to McGuireWoods

Sandoz eyes US biosimilar launch as Regeneron settles

Killing the golden goose of US drug innovation (Part I): Follow the money

Buchalter brings in new partner to head up medtech

Trump’s march-in rights threat: Why pharma is rethinking collaborations

UK gets new IP minister following cabinet reshuffle

Barnes & Thornburg reveals five new IP leaders

UK court overturns Genentech patent, cites Brexit in CJEU referral

More on this story

Editor's picks

Editor's picks

More features